OSE Immunotherapeutics: launch of phase 3 study

(CercleFinance.com) - OSE Immunotherapeutics fell by more than 10% on Tuesday on the Paris stock exchange, despite the launch of its Phase 3 trial for its therapeutic lung cancer vaccine project.


The international trial, dubbed 'Artemia', will evaluate the efficacy of the Tedopi vaccine as a second-line treatment for patients suffering from non-small cell lung cancer (NSCLC).

The aim is to demonstrate that participants' immune systems can be re-armed, thereby prolonging the survival of metastatic patients.

The study, which has been approved by international health agencies in 14 countries (USA, Canada, Europe and UK), aims to support the registration of Tedopi, combined with a companion diagnostic test to identify HLA-A2 positive patients.

NSCLC accounts for 85% of all lung cancers, and the HLA-A2 phenotype is found in around 45% of the global population.

Despite this good news, OSE Immuno shares were one of the biggest decliners on the Paris market on Tuesday.

The problem is that we now know that non-small-cell lung cancer is a very crowded market, and investors' attention has 'already been diverted to other OSE projects, such as OSE127 in hemorrhagic rectocolitis (UC)', explains one trader.

Copyright (c) 2024 CercleFinance.com. All rights reserved.